In the Clinic

Our lead investigational drug, OP-1250, is a novel oral compound developed to completely antagonize the estrogen receptor (ER) and block the ER-mediated cancer cell growth and proliferation signal.

OP-1250 Pipeline

Target Patient Population

Discovery

Nonclinical

Phase I

Phase II

Phase III

Clinical
Collaboration

ER+/HER2- Metastatic Breast Cancer

2/3 Line Monotherapy
(with and without CNS metastases)

Combo Therapy with CDK 4/6i palbociclib

Combo Therapy with CDK 4/6i ribociclib

Combo Therapy with PI3Ki alpelisib with PIK3CA mutated

Combo Therapy with other agents(1)

ER+/HER2+ Metastatic Breast Cancer with CNS METS

Combo Therapy with CNS metastases

Gynecology — Oncology

Endometrial Cancer(1)

Gynecologic malignancies

Discovery Pipeline

Target Patient Population

Discovery

Nonclinical

Phase I

Phase II

Phase III

Clinical
Collaboration

Breast Cancer target

Undisclosed Oncology target

Clinical Trials

OP-1250 is currently in development as a treatment for estrogen receptor-positive, HER2-negative metastatic breast cancer (ER+/HER2- MBC), in both monotherapy and combination settings.

Learn more about our culture.